Logo Image
|Articles|June 15, 2002

BioPharm International

  • BioPharm International-06-01-2002
  • Volume 15
  • Issue 6

Negotiating and Structuring Strategic Alliances

by David Schulman, Dechert London; and Joe Zammit-Lucia, Chris Easley, Cambridge Pharma Consultancy The job of many a biotech CEO is scrambling to find and secure funds to support the company's development projects. For many biopharmaceutical companies in early development stages, collaboration with "big pharma" is a compelling answer to the cashflow problem. But strategic alliances should benefit those on both sides of the negotiating table.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 24 years ago

Finding Funding in Biotechnology: Keeping the Companies Alive

over 24 years ago

Biotechnology Patent Holders Beware! A Supreme Court Ruling may Significantly Reduce the Value of Your Patent Portfolio

over 24 years ago

Guest Editorial: Enabling Collaboration in the Pharmaceutical Industry

over 24 years ago

Stem Cells and Xenotransplantation: Ethics, Patents, and Politics

over 24 years ago

Unlocking the Value of R&D: Managing the Risks

over 24 years ago

Viewpoint: United Kingdom highlights biomanufacturing capabilities

over 24 years ago

Creating Effective Biopharmaceutical QA/QC Organizations: Your People are the Key

over 24 years ago

Inside Washington: Safety, Risk, and Biotechnology Regulation

over 24 years ago

Criminal Penalties for Theft of Biological Material

over 24 years ago

Outsourcing Outlook: E-Procurement - Reverse Auctions and the Seller's Perspective.

Related to this article

View more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more